Final primary analysis in the original cohort of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with frontline neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer

We hypothesized that adding durvalumab and tremelimumab to neoadjuvant chemotherapy (NACT) in advanced-stage epithelial ovarian cancer (aEOC) would increase progression-free survival (PFS) with minimal adverse effects. Here, we report the final primary endpoint in the original cohort of the KGOG 3046 study on NACT with dual immune checkpoint blockade (durvalumab and tremelimumab) in newly diagnosed aEOC.